Monopar Therapeutics (MNPR) to Release Quarterly Earnings on Thursday

Monopar Therapeutics (NASDAQ:MNPR) is expected to be posting its quarterly earnings results before the market opens on Thursday, March 27th. Analysts expect Monopar Therapeutics to post earnings of ($0.37) per share for the quarter.

Monopar Therapeutics Price Performance

MNPR stock opened at $39.10 on Thursday. Monopar Therapeutics has a 1-year low of $1.72 and a 1-year high of $54.30. The firm has a fifty day moving average price of $36.46 and a two-hundred day moving average price of $22.11. The firm has a market cap of $238.59 million, a price-to-earnings ratio of -19.85 and a beta of 1.18.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on MNPR shares. Piper Sandler restated an “overweight” rating and set a $76.00 price target on shares of Monopar Therapeutics in a research report on Wednesday. HC Wainwright upped their price target on shares of Monopar Therapeutics from $22.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, January 22nd.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.